Lynparza Approved in Japan to Treat Certain Advanced Ovarian Cancers

Lynparza Approved in Japan to Treat Certain Advanced Ovarian Cancers

282648

Lynparza Approved in Japan to Treat Certain Advanced Ovarian Cancers

Lynparza (olaparib) has been approved in Japan as a maintenance treatment for women with advanced ovarian cancer who responded to a first-line chemotherapy regimen containing bevacizumab, AstraZeneca and Merck announced in a press release. The approval, for patients whose cancer is positive for homologous recombination deficiency (HRD), is based on data from the PAOLA-1 Phase 3 trial (NCT02477644), in which oral Lynparza significantly extended the time patients lived without disease worsening by about 1.5 years. Similar approvals have…

You must be logged in to read/download the full post.